Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wilks

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Blood|August 20, 2025
Gene Therapy for HbSC Disease and other Compound Heterozygous Sickle Hemoglobinopathies: A Time for InclusionAndrew Wilks, Martin H Steinberg, Haydar Frangoul
Leukemia Research|September 20, 2023
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulationsShyam A Patel, Elisa Bello, Andrew Wilks, et al.
Investigational New Drugs|March 28, 2012
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agentMatthew Burge, Alessandra B Francesconi, Dusan Kotasek, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing TherapiesBraden Pate, Anna Goldstein, Madeline Labott, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Blood|August 20, 2025
Gene Therapy for HbSC Disease and other Compound Heterozygous Sickle Hemoglobinopathies: A Time for InclusionAndrew Wilks, Martin H Steinberg, Haydar Frangoul
Leukemia Research|September 20, 2023
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulationsShyam A Patel, Elisa Bello, Andrew Wilks, et al.
Investigational New Drugs|March 28, 2012
Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agentMatthew Burge, Alessandra B Francesconi, Dusan Kotasek, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing TherapiesBraden Pate, Anna Goldstein, Madeline Labott, et al.
Pageof 1